Stability of transmitted drug-resistant HIV-1 species

被引:27
作者
Cane, PA [1 ]
机构
[1] Hlth Protect Agcy, Ctr Infect, Salisbury SP4 0JG, Wilts, England
关键词
HIV-1; persistence of mutations; transmitted resistance;
D O I
10.1097/01.qco.0000191506.10363.e1
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose of review The proportion of patients showing primary infection with HIV-1 that are already resistant to antiviral drugs has been steadily increasing. Such resistance is known to compromise therapy response. Most patients, however, are not diagnosed during their incident infection and, until recently, it was not known for how long resistant virus can be detected following infection. This article reviews reports on the stability of transmitted resistance in the absence of therapy. Recent findings It has now been shown that many resistance-associated mutations can persist for a considerable time following transmission in the absence of treatment and that such resistance can be further transmitted. Summary Since transmitted resistance can be detected years after infection, it is now worthwhile carrying out resistance tests on newly diagnosed patients in which it is known that the level of transmitted resistance in the population warrants such testing.
引用
收藏
页码:537 / 542
页数:6
相关论文
共 29 条
  • [1] Atchison RE, 2005, ANTIVIR THER, V10, pS45
  • [2] Persistence of primary drug resistance among recently HIV-1 infected adults
    Barbour, JD
    Hecht, FA
    Wrin, T
    Liegler, TJ
    Ramstead, CA
    Busch, MP
    Segal, MR
    Petropoulos, CJ
    Grant, RM
    [J]. AIDS, 2004, 18 (12) : 1683 - 1689
  • [3] Bennett DE, 2005, ANTIVIR THER, V10, pS27
  • [4] What can modeling tell us about the threat of antiviral drug resistance?
    Blower, S
    Volberding, P
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2002, 15 (06) : 609 - 614
  • [5] Persistence of mutidrug-resistant HIV-1 in primary infection leading to superinfection
    Brenner, B
    Routy, J
    Quan, YD
    Moisi, D
    Oliveira, M
    Turner, D
    Wainberg, MA
    Baril, JG
    Bélanger, M
    Côté, P
    Dufresne, S
    Leplante, F
    Lebel, J
    Boissonnault, M
    Lavoie, H
    Lessard, B
    Olivier, C
    Trottier, RB
    Vézina, S
    Gilmore, N
    Klein, M
    Lalonde, P
    MacLeod, J
    Smith, G
    Cholette, P
    Laponte, N
    Samson, J
    Frenette, C
    Valois, C
    Bélanger, M
    [J]. AIDS, 2004, 18 (12) : 1653 - 1660
  • [6] CANE P, 2004, 11 C RETR OPP INF SA
  • [7] Cane PA, 2004, ANTIVIR THER, V9, pU83
  • [8] Analysis of HIV-1 variation in blood and semen during treatment and treatment interruption
    Choudhury, B
    Pillay, D
    Taylor, S
    Cane, PA
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2002, 68 (04) : 467 - 472
  • [9] Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus
    de Ronde, A
    van Dooren, M
    van der Hoek, L
    Bouwhuis, D
    de Rooij, E
    van Gemen, B
    de Boer, R
    Goudsmit, J
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (02) : 595 - 602
  • [10] Delaugerre C, 2004, ANTIVIR THER, V9, P415